Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
Status:
Recruiting
Trial end date:
2032-12-01
Target enrollment:
Participant gender:
Summary
Methylphenidate (MPH) is the first-line pharmacological treatment for adults with
Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable
interindividual variability regarding the dose required, tolerability and response rates to
MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment
outcomes in ADHD.
Phase:
Phase 4
Details
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Collaborators:
Conselho Nacional de Desenvolvimento Científico e Tecnológico Coordination for the Improvement of Higher Education Personnel Federal University of Rio Grande do Sul